Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tremtelectogene empogeditemcel

A preparation of allogeneic, human leukocyte antigen (HLA) matched, cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (HSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to remove the cluster of differentiation 33 (CD33) antigen, that can potentially be used to improve hematopoietic recovery after hematopoietic cell transplantation (HCT) and CD33-targeting chemotherapy. Upon administration, tremtelectogene empogeditemcel increases and restores the number of HSPCs, which may prevent or decrease infection and other complications of HCT and chemotherapy-induced neutropenia (CIN). The removal of CD33 protects VOR33 from the cytotoxic effects of CD33-targeted agents administered after HCT.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive hematopoietic stem and progenitor cells VOR33
allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive HSCs VOR33
allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive HSPCs VOR33
eHSCs VOR33
Trem-cel
Code name:VOR 33
VOR-33
VOR33
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search